2025 HCPCS Code Q0220

Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg

TAGS: recommended years compromised adverse severely available vaccine reaction least pediatric tixagevimab older moderate known prophylaxis certain individuals severe history immune systems vaccination adults either weighing
NoticeHCPCS Q0220 terminated on December 12, 2024.
Short DescriptionTixagev and cilgav, 300mg
HCPCS Action Code N - No maintenance for this code
HCPCS Coverage Code C - Carrier judgment
HCPCS Code Added Date December 08, 2021
HCPCS Action Effective Date December 13, 2024
HCPCS Pricing Indicator Code 54 - Vaccinations
HCPCS Type Of Service Code V - Pneumococcal/flu vaccine (eff 01/96), Pneumococcal/flu/hepatitis B vaccine (eff 04/95-12/95), Pneumococcal only before 04/95
HCPCS Multiple Pricing Indicator Code A - Not applicable as HCPCS priced under one methodology
HCPCS Anesthesia Base Unit Quantity 0
HCPCS Coverage Issues Manual Reference Section Number

Check Similar HCPCS Codes